<DOC>
	<DOCNO>NCT03071003</DOCNO>
	<brief_summary>Sensorion study sponsor objective study investigate safety pharmacokinetic ( PK ) profile SENS 401 human single repeat dose administration confirm , interconversion ( R ) enantiomer ( S ) enantiomer . The study involve one drug , refer SENS-401.The key objective ass safety SENS 401 multiple dos healthy subject . The population eligible take part study healthy male female , non-smoking volunteer , age 18 50 year , determine screen test Simbec . Participation trial last 3 week ( first screen final end study visit ) .</brief_summary>
	<brief_title>A Study SENS 401 Healthy Subjects</brief_title>
	<detailed_description>This randomise , double blind , multiple dose , safety PK study . Three cohort 12 subject administer three different dose regimen . Screening assessment carry within 14 day administration investigational medicinal product ( IMP ) . Eligible subject ask return treatment period . Cohort 1 : 12 subject receive 29 mg SENS-401 placebo daily 7 day . Cohort 2 : 12 subject receive 29 mg SENS-401 placebo twice daily 6 day single dose 29 mg SENS-401 placebo morning Day 7 . Cohort 3 : 12 subject receive 43.5 mg SENS-401 placebo twice daily 6 day single dose 43.5 mg SENS-401 placebo morning Day 7 . Subjects ask attend Simbec 5-7 day administration last dose post study visit . If withdrawn study , still ask attend end study assessment . Subjects may ask return need follow .</detailed_description>
	<mesh_term>Ear Diseases</mesh_term>
	<mesh_term>Labyrinth Diseases</mesh_term>
	<mesh_term>Labyrinthitis</mesh_term>
	<criteria>1 . Healthy male female ( non pregnant/non lactate ) 18 50 year age . 2 . Female subject child bear potential negative pregnancy test screen visit willing use 2 effective method contraception , first dose 3 month afterwards ( i.e. , 3 month last SENS401 dose ) . 3 . Female subject non child bear potential negative pregnancy test screen visit . For purpose study , define subject amenorrheic least 12 consecutive month least 4 month post surgical sterilisation ( include bilateral fallopian tube ligation bilateral oophorectomy without hysterectomy ) level follicle stimulate hormone ( FSH ) fall within respective pathology reference range . In event subject 's menopause status clearly establish ( example , subject indicate amenorrheic 10 year ) , FSH level consistent post menopausal condition , determination subject eligibility discretion Investigator follow consultation Sponsor 's Responsible Physician . 4 . Male subject willing use 2 effective method contraception , ( unless anatomically sterile ) first dose 3 month afterwards ( i.e. , 3 month last SENS401 dose ) . 5 . Subject body mass index ( BMI ) 18 30 kg/m2 . If Asians include , BMI value modify 1623 kg/m2 ( range consider normal Asian population ) . BMI = body weight ( kg ) /height ( ) 2 . 6 . Subject clinically significant abnormal serum biochemistry , haematology urine examination value within 14 day first dose . 7 . Subject negative urinary drug abuse screen , determine within 14 day first dose ( positive alcohol result may repeat discretion Investigator ) . 8 . Subject negative human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( Hep B ) hepatitis C virus antibody ( Hep C ) result . 9 . Subject clinically significant abnormality 12 lead electrocardiogram ( ECG ) determine within 14 day first dose . 10 . Subject clinically significant abnormality blood pressure pulse determine within 14 day first dose . 11 . Subject non smoker ex smoker smoke last 3 month ( determine urine cotinine &lt; 500 ng/mL screen visit ) . 12 . Subject available complete study ( include follow visit ) comply study restriction . 13 . Subject satisfies medical examiner fitness participate study . 14 . Subject provide write informed consent participate study . 1 . Subject clinically significant history gastrointestinal disorder likely influence drug absorption . 2 . Subject receipt regular medication ( exception contraception ) within 14 day first dose may impact safety objective study ( Investigator 's discretion ) . 3 . Subject evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . 4 . Subject renal ( serum creatinine ( CREAT ) level &gt; 1.5 fold upper limit normal ( ULN ) liver insufficiency ( alkaline phosphatase ( ALP ) level &gt; 1.2 fold ULN , gamma glutamyl transferase ( GGT ) , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) level &gt; 2.5 fold ULN , total bilirubin ( BIL T ) level &gt; 1.5 fold ULN ) . 5 . Subject history , family history ( immediate relative ) , long QT syndrome Torsade de Pointes symptomatic bradycardia . 6 . Subject clinically significant history previous allergy / sensitivity SENS218 excipients 5hydroxytryptamine ( 5 HT3 ) receptor antagonist . 7 . Subject clinically significant history drug alcohol abuse . 8 . Subject inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . 9 . Subject participation New Chemical Entity clinical study within previous 4 month market drug clinical study within previous 3 month . ( N.B . washout period study define period time elapse last dose previous study first dose next study ) . 10 . Subject donate 450 mL blood within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Volunteer Study</keyword>
</DOC>